Last updated on June 2019

Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia

Brief description of study

The primary objective of the study is to evaluate the reduction of LDL-C by evinacumab in comparison to placebo after 16 weeks in patients with primary hypercholesterolemia (HeFH, or non-HeFH with a history of clinical ASCVD) with persistent hypercholesterolemia despite receiving maximally-tolerated LMT. Persistent hypercholesterolemia is defined as LDL-C 70 mg/dL (1.81 mmol/L) for those patients with clinical ASCVD and LDL-C 100 mg/dL (2.59 mmol/L) for those patients without clinical ASCVD.

Clinical Study Identifier: NCT03175367

Find a site near you

Start Over

Academic Medical Center

Amsterdam, Netherlands
  Connect »